Coverage update: 18 September 2026
The US FDA announced approval of Besremi (ropeginterferon alfa-2b-njft) for adults with essential thrombocythemia. Essential thrombocythemia is a chronic myeloproliferative neoplasm characterised by clonal platelet overproduction and variable thrombotic, bleeding and disease-progression risks.
What is known
The approval expands the US regulatory status of ropeginterferon alfa-2b-njft to this indication. Treatment selection in essential thrombocythemia remains risk-based and patient-specific; the approval announcement should be read together with the full prescribing information.
Evidence questions clinicians should ask
- Which population was studied and how was diagnosis confirmed?
- What comparator and endpoints were used?
- How durable were haematological and clinical responses?
- What adverse effects, discontinuations and monitoring requirements were reported?
Limitations and uncertainty
A regulator’s approval does not mean that one medicine is appropriate for every patient. Comparative effectiveness, long-term outcomes and applicability to under-represented groups require careful interpretation.
India status
FDA approval is a United States decision. It does not by itself confirm CDSCO approval, Indian availability, price or reimbursement. Verify the current Indian label and regulatory record before making any claim about local availability.
Primary sources
Related articles
Featured image: National Cancer Institute via Unsplash.
Last reviewed: 19 September 2026
Medical disclaimer: This article is for professional education and news interpretation only. It does not replace patient-specific assessment, local protocols, prescribing information or specialist advice.